Upgrade to SI Premium - Free Trial

Eisai And Biogen (BIIB) to Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

September 13, 2019 8:00 AM
(Updated - September 13, 2019 8:01 AM EDT)Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced the decision to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News

Next Articles